ClinicalTrials.gg
CompletedNCT03088137Updated Apr 1, 2022Results posted

Study to Compare Efficacy and Safety of Primapur and Gonal-f in Women for Assisted Reproductive Treatment

A Phase 3 interventional study of Follitropin alfa (Gonal-f) and Follitropin alfa (Primapur) in Infertility, Female, sponsored by IVFarma LLC. Completed at 3 sites in Russian Federation. Open to female participants aged 20 Years to 35 Years. Per ClinicalTrials.gov, last updated 2022-04-01.

Sponsored by IVFarma LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
Female
01

Study summary

The purpose of this study is to show equivalence with regard to the number of oocytes retrieved between follitropin alfa (pen-injectors) Primapur® and Gonal-f® in woman undergoing IVF/ICSI

02

Conditions studied

  • Infertility, Female

Browse trials for

Keywords

  • in vitro fertilization
03

In context

Infertility, Female

552 studies on the registry are indexed under Infertility, Female; 135 are open to participants now.

This study's enrollment of 118 is above the median of 100 across 378 interventional studies indexed under Infertility, Female.

Browse Infertility, Female studies →

Lead sponsor

IVFarma LLC is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infertility due to tubal factor and/or male factor
  • Age between 20 and 35 years with regular menstrual cycles of 21-35 days
  • First or second cycle in the present series of ART
  • (body mass index) ≥ 18 ≤ 30 kg/m2
  • Basal FSH (follicle stimulating hormone) \< 10 IU/L (cycle day 2-5)
  • E2 (estradiol) levels \< 50pg/mL (cycle day 2)
  • AMH (anti-mullerian hormone) ≥ 1.0 ng/ml
  • Antral follicle ≥ 4 to ≤ 15 follicles (both ovaries)
  • Presence of both ovaries and normal uterine cavity

Exclusion criteria

Exclusion Criteria:

  • Presence of pregnancy
  • to follitropin alfa
  • Ovarian cysts
  • History of ≥2 succeeding ART (assisted reproductive technology) cycles IVF (in vitro fertilization) and/or ICSI (Intracytoplasmic sperm injection) before the study cycle
  • Previous history of severe ovarian hyperstimulation syndrome
  • Presence of polycystic ovaries (PCO)
  • Presence of endometriosis and hydrosalpinx
  • Presence of uterine disorders
  • History of poor (\< 4 oocytes) or hyper (> 25 oocytes) responses to FSH treatment at dose 150 IU and GnRH-antagonist (gonadotropin-releasing hormone) protocol
  • Premature ovarian failure
  • Ectopic pregnancy (3 month before the study cycle)
  • Presence of systemic disease
  • Presence of chronic cardiovascular, hepatic, renal or pulmonary disease
  • Presence of endocrine disorder
  • Neoplasia
  • Male infertility without mobile spermatozoa in the ejaculate, that need MESA (Microsurgical epididymal sperm aspiration)/TESE (testicular sperm extraction)/TESA (testicular sperm aspiration)
  • Smoking > 10 cigarettes/day
  • Narcomania, alcoholism
  • Planned PGS (preimplantation genetic screeneing) /PGD (preimplantation genetic diagnosis)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
118 participants (actual)

Study arms

  • Experimental
    Primapur (Follitropin alfa)

    Drug: Follitropin alfa (Primapur)

  • Active comparator
    Gonal-f (Follitropin alfa)

    Drug: Follitropin alfa (Gonal-f)

Interventions

  • Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation

  • Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation

06

What researchers measure

Primary outcomes

  1. Oocytes (Intention-to-Treat, ITT)

    The total number of retrieved oocytes at the day of ovum pick-up. No more than 37 hours from the introduction of the trigger of ovulation (hCG or GnRH-agonist). The equivalence in the number of retrieved oocytes was tested using a predetermined equivalence margin of +/- 3.4 oocytes.

    Time frame: From date of randomization up to 18 days

Secondary outcomes

  1. Number of Follicles With Size ≥ 16 mm

    The number of follicles 16 mm or over in diameter at the day of hCG (or GnRH-agonist) administration

    Time frame: From date of randomization up to 16 days

  2. Mature Oocytes

    The number of mature oocytes (MII stage of development)

    Time frame: From date of randomization up to 18 days

  3. Fertilised Oocytes

    The number of fertilised oocytes with the presence of two pronuclei: 2PN

    Time frame: From date of randomization up to 19 days

  4. Percentage of Patients With Embryo Transfer

    The number of patients (and percentage) with embryo transfers on days 3 and 5 after ovum pick-up

    Time frame: From date of randomization up to 25 days

  5. Total Dose of Follitropin Alfa

    The total dose of the follitropin alfa administrated during the ovarian hyperstimulation protocol (measured in International Units - IU)

    Time frame: From date of randomization up to 16 days

  6. Number of Days of Follitropin Alfa Treatment

    The duration of ovarian hyperstimulation protocol (at the day of trigger of ovulation)

    Time frame: From date of randomization up to 16 days

  7. Number of Patients With Follitropin Alfa Dose Correction

    The number of dose adjustments during the ovarian hyperstimulation protocol (increment 25-50 IU)

    Time frame: From date of randomization up to 16 days

  8. Number of Patients With Cycle Cancellation

    The number of the ovarian hyperstimulation protocol cancellation (at the day of trigger of ovulation)

    Time frame: From date of randomization up to 16 days

  9. Number of No-responders

    The number of patients with no response to follitropin alfa treatment (absence of growing follicles, no any oocytes obtained at the day of ovum pick-up)

    Time frame: From date of randomization up to 8 days

  10. Percentage of Patients With Serum hCG More Than 25 IU/l

    Biochemical pregnancy test: serum hCG more than 25 IU/l (days 12-17 after embryo transfer)

    Time frame: From date of randomization up to 42 days

  11. Percentage of Patients With the Evidence for Clinical Pregnancy

    Confirmation of clinical pregnancy: ultrasound detection of intrauterine gestational sac and heart activity

    Time frame: The 10th week after embryo transfer

07

Results

Posted Jun 6, 2019

Participant flow

Subjects were screened and enrolled at 3 In Vitro Fertilisation (IVF) centers in Russian Federation from 08.02.2017 - 17.08.2018.

Participant flow — Overall Study
MilestonePrimapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)
Started5555
Completed5555
Not completed00

Outcome measures

PrimaryOocytes (Intention-to-Treat, ITT)

The total number of retrieved oocytes at the day of ovum pick-up. No more than 37 hours from the introduction of the trigger of ovulation (hCG or GnRH-agonist). The equivalence in the number of retrieved oocytes was tested using a predetermined equivalence margin of +/- 3.4 oocytes.

Time frame:
From date of randomization up to 18 days
Reported as:
Mean · Number of retrieved oocytes
Oocytes (Intention-to-Treat, ITT)
Number of retrieved oocytesPrimapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)
Oocytes (Intention-to-Treat, ITT)12.16 ± 7.2811.62 ± 6.29
Statistical analysis
  • Primapur (Follitropin Alfa) vs Gonal-f (Follitropin Alfa) · Wilcoxon (Mann-Whitney) · p = 0.002 · Mean difference (final values): 0.546 · 95% CI -2.026 to 3.116
SecondaryNumber of Follicles With Size ≥ 16 mm

The number of follicles 16 mm or over in diameter at the day of hCG (or GnRH-agonist) administration

Time frame:
From date of randomization up to 16 days
Reported as:
Mean · Number of follicles
Number of Follicles With Size ≥ 16 mm
Number of folliclesPrimapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)
Number of Follicles With Size ≥ 16 mm12.09 ± 6.15911.38 ± 4.965
Statistical analysis
  • Primapur (Follitropin Alfa) vs Gonal-f (Follitropin Alfa) · Wilcoxon (Mann-Whitney) · p = 0.806 · Mean difference (final values): 0.709 · 95% CI -1.405 to 2.824
SecondaryMature Oocytes

The number of mature oocytes (MII stage of development)

Time frame:
From date of randomization up to 18 days
Reported as:
Mean · Number of mature oocytes (MII stage)
Mature Oocytes
Number of mature oocytes (MII stage)Primapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)
Mature Oocytes9.64 ± 6.2709.86 ± 5.546
Statistical analysis
  • Primapur (Follitropin Alfa) vs Gonal-f (Follitropin Alfa) · Wilcoxon (Mann-Whitney) · p = 0.617 · Mean difference (final values): 0.218 · 95% CI -2.455 to 2.019
SecondaryFertilised Oocytes

The number of fertilised oocytes with the presence of two pronuclei: 2PN

Time frame:
From date of randomization up to 19 days
Reported as:
Mean · Number of oocytes with 2PN
Fertilised Oocytes
Number of oocytes with 2PNPrimapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)
Fertilised Oocytes8.127 ± 6.6088.764 ± 5.850
Statistical analysis
  • Primapur (Follitropin Alfa) vs Gonal-f (Follitropin Alfa) · Wilcoxon (Mann-Whitney) · p = 0.445 · Mean difference (final values): 0.636 · 95% CI -2.995 to 1.723
SecondaryPercentage of Patients With Embryo Transfer

The number of patients (and percentage) with embryo transfers on days 3 and 5 after ovum pick-up

Time frame:
From date of randomization up to 25 days
Reported as:
Count of participants · Participants
Percentage of Patients With Embryo Transfer
ParticipantsPrimapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)
Embryo transfer on day 3 (%)119
Embryo transfer on day 5 (%)3840
Statistical analysis
  • Primapur (Follitropin Alfa) vs Gonal-f (Follitropin Alfa) · ANOVA · p = 0.623
SecondaryTotal Dose of Follitropin Alfa

The total dose of the follitropin alfa administrated during the ovarian hyperstimulation protocol (measured in International Units - IU)

Time frame:
From date of randomization up to 16 days
Reported as:
Mean · Total dose (IU)
Total Dose of Follitropin Alfa
Total dose (IU)Primapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)
Total Dose of Follitropin Alfa1532.7 ± 267.21517.9 ± 255.2
Statistical analysis
  • Primapur (Follitropin Alfa) vs Gonal-f (Follitropin Alfa) · Wilcoxon (Mann-Whitney) · p = 0.488 · Mean difference (final values): 14.9 · 95% CI -83.9 to 113.6
SecondaryNumber of Days of Follitropin Alfa Treatment

The duration of ovarian hyperstimulation protocol (at the day of trigger of ovulation)

Time frame:
From date of randomization up to 16 days
Reported as:
Mean · Days
Number of Days of Follitropin Alfa Treatment
DaysPrimapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)
Number of Days of Follitropin Alfa Treatment9.745 ± 1.0759.727 ± 1.027
Statistical analysis
  • Primapur (Follitropin Alfa) vs Gonal-f (Follitropin Alfa) · Wilcoxon (Mann-Whitney) · p = 0.629 · Mean difference (final values): 0.018 · 95% CI -0.379 to 0.416
SecondaryNumber of Patients With Follitropin Alfa Dose Correction

The number of dose adjustments during the ovarian hyperstimulation protocol (increment 25-50 IU)

Time frame:
From date of randomization up to 16 days
Reported as:
Count of participants · Participants
Number of Patients With Follitropin Alfa Dose Correction
ParticipantsPrimapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)
Number of Patients With Follitropin Alfa Dose Correction1311
Statistical analysis
  • Primapur (Follitropin Alfa) vs Gonal-f (Follitropin Alfa) · Wilcoxon (Mann-Whitney) · p = 0.644
SecondaryNumber of Patients With Cycle Cancellation

The number of the ovarian hyperstimulation protocol cancellation (at the day of trigger of ovulation)

Time frame:
From date of randomization up to 16 days
Reported as:
Count of participants · Participants
Number of Patients With Cycle Cancellation
ParticipantsPrimapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)
Number of Patients With Cycle Cancellation00
SecondaryNumber of No-responders

The number of patients with no response to follitropin alfa treatment (absence of growing follicles, no any oocytes obtained at the day of ovum pick-up)

Time frame:
From date of randomization up to 8 days
Reported as:
Count of participants · Participants
Number of No-responders
ParticipantsPrimapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)
Number of No-responders00
SecondaryPercentage of Patients With Serum hCG More Than 25 IU/l

Biochemical pregnancy test: serum hCG more than 25 IU/l (days 12-17 after embryo transfer)

Time frame:
From date of randomization up to 42 days
Reported as:
Number · Percentage of patients (%)
Percentage of Patients With Serum hCG More Than 25 IU/l
Percentage of patients (%)Primapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)
Percentage of Patients With Serum hCG More Than 25 IU/l34.7 (21.4 to 48.0)36.7 (23.2 to 50.2)
Statistical analysis
  • Primapur (Follitropin Alfa) vs Gonal-f (Follitropin Alfa) · Chi-squared · p = 0.833 · Mean difference (final values): -2.0 · 95% CI -21.0 to 17.0
SecondaryPercentage of Patients With the Evidence for Clinical Pregnancy

Confirmation of clinical pregnancy: ultrasound detection of intrauterine gestational sac and heart activity

Time frame:
The 10th week after embryo transfer
Reported as:
Number · Percentage of patients (%)
Percentage of Patients With the Evidence for Clinical Pregnancy
Percentage of patients (%)Primapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)
Percentage of Patients With the Evidence for Clinical Pregnancy26.5 (14.1 to 38.9)32.7 (19.6 to 45.8)
Statistical analysis
  • Primapur (Follitropin Alfa) vs Gonal-f (Follitropin Alfa) · Chi-squared · p = 0.507 · Mean difference (final values): -0.62 · 95% CI -24.3 to 11.9

Adverse events

Collected over 1 year, 6 month. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Primapur (Follitropin Alfa)0/55 (0%)2/55 (3.6%)21/55 (38.2%)
Gonal-f (Follitropin Alfa)0/55 (0%)2/55 (3.6%)13/55 (23.6%)
Most frequent serious events
Most frequent serious events
EventPrimapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)
Ovarian hyperstymulation syndromeReproductive system and breast disorders0/552/55
Iatrogenic injuryInjury, poisoning and procedural complications1/550/55
Threatened miscarriagePregnancy, puerperium and perinatal conditions1/550/55
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPrimapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)
Ovarian hyperstimulation syndromeReproductive system and breast disorders4/552/55
Lower abdominal painPregnancy, puerperium and perinatal conditions2/554/55
Lower abdominal painReproductive system and breast disorders3/551/55
Abnormal vaginal bleedingReproductive system and breast disorders3/551/55
Spontaneous miscarriagePregnancy, puerperium and perinatal conditions0/552/55
Decrease in breast sensitivityReproductive system and breast disorders2/550/55
SpottingReproductive system and breast disorders2/550/55
Early Toxicosis During PregnancyPregnancy, puerperium and perinatal conditions0/551/55
Abnormal vaginal bleedingPregnancy, puerperium and perinatal conditions0/551/55
MensesReproductive system and breast disorders0/551/55

Baseline characteristics

Age, Continuous
Age, Continuous(years)Primapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)Total
Mean31.3 ± 2.6830.0 ± 2.7130.65 ± 2.75
Sex: Female, Male
Sex: Female, Male(Participants)Primapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)Total
Female5555110
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Primapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White5555110
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Primapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)Total
Russia5555110
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m2)Primapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)Total
Mean22.0 ± 2.6922.3 ± 3.0622.15 ± 2.87
Duration of infertility
Duration of infertility(month)Primapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)Total
Mean46.4 ± 32.436.9 ± 26.641.65 ± 28.22
Antral follicle
Antral follicle(Number of antral follicles)Primapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)Total
Mean11.2 ± 3.212.4 ± 2.411.80 ± 2.87
Anti-mullerian hormone (AMH)
Anti-mullerian hormone (AMH)(ng per ml)Primapur (Follitropin Alfa)Gonal-f (Follitropin Alfa)Total
Mean4.57 ± 2.965.47 ± 3.825.02 ± 3.43

3 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • Clinical Hospital Lapino
    Moscow Oblast, Russian Federation
  • AltraVita IVF clinic
    Moscow, Russian Federation
  • Perinatal Medical Center
    Moscow, Russian Federation
09

References and documents

Publications

  • M. Polzikov, Z. Barakhoeva, S. Yakovenko, M. Ovchinnikova, L.Vovk, Y. Fetisova. A multicenter, randomized study comparing the efficacy of follitropin alpha biosimilar and the original follitropin alpha. Abstracts of the 35th Annual Meeting of the ESHRE, Vienna, Austria 24 to 26 June 2019 (abstract P-649), Human Reproduction, 2019; Vol. 34, Suppl. 1, p. i439.
  • Barakhoeva Z, Vovk L, Fetisova Y, Marilova N, Ovchinnikova M, Tischenko M, Scherbatyuk Y, Kolotovkina A, Miskun A, Kasyanova G, Teterina T, Zorina I, Belousova N, Morozova E, Yakovenko S, Apryshko V, Sichinava L, Shalinsmall a, Cyrillic R, Polzikov M. A multicenter, randomized, phase III study comparing the efficacy and safety of follitropin alpha biosimilar and the original follitropin alpha. Eur J Obstet Gynecol Reprod Biol. 2019 Oct;241:6-12. doi: 10.1016/j.ejogrb.2019.07.032. Epub 2019 Jul 26. PubMed 31400644 ↗
  • Barakhoeva Z.B., Vovk L.A., Zorina I.V., Belousova N.Y., Teterina T.A., Yakovenko S.A., Apryshko V.P., Fetisova Y.A., Marilova N.A., Morozova E.G., Ovchinnikova M.M., Tishenko M.A., Sherbatyuk Y.V., Kolotovkina A.V., Miskun A.A., Kasyanova G.V., Sichinava L.G., Shalinа R.I., Polzikov M.A. Major results of a phase III comparative multicenter study on the follitropin alfa biosimilar (Primapur®) and the original follitropin alfa (Gonal-f®). Akusherstvo, ginekologiya i reprodukciya. 2018;12(3):5-16. (In Russ.) https://doi.org/10.17749/2313-7347.2018.12.3.005-016
  • Polzikov M, Blinov D, Barakhoeva Z, Vovk L, Fetisova Y, Ovchinnikova M, Tischenko M, Zorina I, Yurasov V, Ushakova T, Sergeyev O. Association of the Serum Folate and Total Calcium and Magnesium Levels Before Ovarian Stimulation With Outcomes of Fresh In Vitro Fertilization Cycles in Normogonadotropic Women. Front Endocrinol (Lausanne). 2022 Feb 11;13:732731. doi: 10.3389/fendo.2022.732731. eCollection 2022. PubMed 35222266 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Aug 2018, 18 months.

Results were first posted in Jun 2019, 9 months after primary completion.

Of 28 phase 3 interventional studies under Infertility, Female, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2017
First posted
Mar 23, 2017
StartActual
Feb 8, 2017
Primary completionActual
Aug 17, 2018
CompletionActual
Aug 17, 2018
Results first posted
Jun 6, 2019
Last update
Apr 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03088137
Lead sponsor
IVFarma LLC
Collaborators
BridgePharm LLC, GlobalPharma LLC
Responsible party
Sponsor
First posted
Mar 23, 2017
Start date
Feb 8, 2017
Primary completion
Aug 17, 2018
Completion
Aug 17, 2018
Results posted
Jun 6, 2019
Last update
Apr 1, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin alfa

Start the discussion